Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate
Background: Outcomes-based reimbursement (OBR) can reduce decision uncertainty and accelerate patient access to cell and gene therapies, however, OBR is rarely applied in practice in England. Oncology is the therapy area with the most cell and gene therapies in late-stage development, and the System...
Main Authors: | Jesper Jørgensen, Panos Kefalas |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-01-01
|
Series: | Journal of Market Access & Health Policy |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/20016689.2019.1635842 |
Similar Items
-
Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test
by: Jesper Jørgensen, et al.
Published: (2017-01-01) -
Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
by: Virginia Ronco, et al.
Published: (2021-03-01) -
Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
by: Jesper Jørgensen, et al.
Published: (2020-01-01) -
A systematic review of non-standard dosing of oral anticancer therapies
by: Faouzi Djebbari, et al.
Published: (2018-11-01) -
Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy
by: Oscar Fabian Garcia-Aponte, et al.
Published: (2021-04-01)